Vertex Pharmaceuticals (NASDAQ:VRTX) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) announced its quarterly earnings data on Monday. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06), FiscalAI reports. The firm had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Third-quarter revenue rose 12% year over year, and Vertex raised full-year 2026 revenue guidance to $13.15 billion-$13.25 billion, reflecting continued CF performance and growing contributions from CASGEVY, JOURNAVX, and PALSONIFY.
• Commercial momentum remained strong across newer products: ALYFTREK generated $706 million in quarterly sales, CASGEVY revenue increased 30% sequentially to $99 million, JOURNAVX prescriptions surpassed 750,000, and PALSONIFY reached $10 million in September.
• Vertex is preparing for the November 30 FDA decision on povetacicept in IgA nephropathy, highlighting its expected efficacy, tolerability, and once-monthly at-home auto-injector; the company also completed enrollment in the pivotal AMPLITUDE study of inaxaplin and expects interim data in early 2027.
• The company advanced its pipeline by prioritizing VX-017, an allogeneic, off-the-shelf islet cell therapy for type 1 diabetes, with phase I/II dosing underway and a goal of entering pivotal development next year; it also reported encouraging early results for the VX-828 next-generation CF corrector.
• Vertex increased full-year non-GAAP operating expense guidance to approximately $6 billion, including Crinetics-related costs, and incurred roughly $50 million in third-quarter financing and transaction costs; the Crinetics acquisition also added $4.5 billion in term loans at approximately 4.8% interest.

Vertex Pharmaceuticals Stock Performance

VRTX stock traded down $5.73 during midday trading on Monday, reaching $553.15. The company’s stock had a trading volume of 3,051,427 shares, compared to its average volume of 1,388,968. The firm has a market capitalization of $140.39 billion, a price-to-earnings ratio of 32.20, a PEG ratio of 2.68 and a beta of 0.28. Vertex Pharmaceuticals has a 1 year low of $403.16 and a 1 year high of $568.67. The stock has a fifty day simple moving average of $523.21 and a two-hundred day simple moving average of $479.47.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on VRTX shares. UBS Group raised their price objective on Vertex Pharmaceuticals from $585.00 to $615.00 and gave the company a “buy” rating in a research report on Monday, September 28th. Barclays lifted their target price on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 16th. TD Cowen lifted their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Finally, Cantor Fitzgerald raised their price objective on shares of Vertex Pharmaceuticals from $590.00 to $595.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $579.81.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.